BioSpace News Archive

NeuPath Health Inc., owner and operator of a network of clinics delivering category-leading chronic pain treatment, announced the voting results from its Annual General and Special Meeting of Shareholders held on June 22, 2022 and the issuance of stock options and restricted share units.

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to BioNTech’s fully owned product candidate BNT211 for the third- or later-line treatment of testicular germ cell tumors.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), today announced that the Italian Medicines Agency, or Agenzia Italiana del Farmaco (AIFA), has authorized Alterity to conduct its Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

Select Medical Corporation and Inova Health System announced a joint venture to own and operate the first critical illness recovery hospital in Northern Virginia.

Tevogen Bio, a late-stage biotechnology company specializing in developing cell and gene therapies in oncology, neurology, and virology, today announced that its Board of Directors has appointed Kendell R. Sprott, M.D., J.D., to its Corporate Advisory Board.

Bench International, a leading global executive search firm, announces the launch of its Digitization of Healthcare Technology practice.

ANGLE plc, a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and allotted 144,999 new ordinary shares of £0.10 each in the Company.

The U.S. Intravenous Immunoglobulin market size was estimated at US$ 6.21 billion in 2021 and is expected to hit US$ 12.24 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.1% from 2022 to 2030.

The global skin antiseptic products market was surpassed at USD 252.3 million in 2021 and is expected to hit around USD 478.5 million by 2030, growing at a CAGR of 8.2% from 2022 to 2030.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), anticipates releasing topline data from Part A of its ongoing Phase 2 study of ANEB-001 on July 5th.